Malik Kahook
Concepts (447)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glaucoma | 61 | 2025 | 221 | 14.990 |
Why?
| Intraocular Pressure | 71 | 2025 | 299 | 10.010 |
Why?
| Glaucoma, Open-Angle | 29 | 2024 | 102 | 6.820 |
Why?
| Trabecular Meshwork | 23 | 2019 | 79 | 5.520 |
Why?
| Glaucoma Drainage Implants | 18 | 2022 | 46 | 5.150 |
Why?
| Antihypertensive Agents | 27 | 2019 | 485 | 4.710 |
Why?
| Trabeculectomy | 17 | 2025 | 72 | 4.290 |
Why?
| Preservatives, Pharmaceutical | 12 | 2024 | 26 | 3.990 |
Why?
| Angiogenesis Inhibitors | 15 | 2021 | 218 | 3.720 |
Why?
| Ocular Hypertension | 18 | 2024 | 67 | 3.580 |
Why?
| Conjunctiva | 13 | 2012 | 51 | 3.290 |
Why?
| Filtering Surgery | 9 | 2016 | 22 | 3.280 |
Why?
| Ophthalmic Solutions | 18 | 2024 | 75 | 3.200 |
Why?
| Benzalkonium Compounds | 11 | 2024 | 15 | 2.740 |
Why?
| Tonometry, Ocular | 23 | 2021 | 89 | 2.500 |
Why?
| Vascular Endothelial Growth Factor A | 12 | 2021 | 528 | 2.430 |
Why?
| Timolol | 8 | 2019 | 14 | 2.290 |
Why?
| Prostaglandins F, Synthetic | 8 | 2014 | 9 | 2.290 |
Why?
| Phacoemulsification | 13 | 2025 | 116 | 2.180 |
Why?
| Ciliary Body | 11 | 2018 | 33 | 1.930 |
Why?
| Glaucoma, Neovascular | 5 | 2015 | 10 | 1.770 |
Why?
| Cloprostenol | 9 | 2013 | 13 | 1.750 |
Why?
| Laser Coagulation | 9 | 2023 | 57 | 1.460 |
Why?
| Lens Implantation, Intraocular | 7 | 2020 | 59 | 1.420 |
Why?
| Antibodies, Monoclonal | 11 | 2011 | 1368 | 1.400 |
Why?
| Cataract Extraction | 6 | 2020 | 97 | 1.390 |
Why?
| Cataract | 8 | 2020 | 208 | 1.380 |
Why?
| Cornea | 8 | 2013 | 128 | 1.360 |
Why?
| Prosthesis Implantation | 8 | 2022 | 148 | 1.360 |
Why?
| Drug Delivery Systems | 7 | 2019 | 337 | 1.260 |
Why?
| Blister | 4 | 2012 | 41 | 1.210 |
Why?
| Retinal Ganglion Cells | 5 | 2016 | 101 | 1.210 |
Why?
| Stents | 5 | 2021 | 504 | 1.170 |
Why?
| Travoprost | 10 | 2014 | 13 | 1.150 |
Why?
| Medication Adherence | 5 | 2016 | 561 | 1.150 |
Why?
| Tomography, Optical Coherence | 6 | 2014 | 186 | 1.140 |
Why?
| Nerve Fibers | 4 | 2012 | 91 | 1.120 |
Why?
| Optic Disk | 6 | 2024 | 40 | 1.110 |
Why?
| Minimally Invasive Surgical Procedures | 3 | 2019 | 175 | 1.080 |
Why?
| Humans | 130 | 2025 | 129847 | 1.070 |
Why?
| Sulfonamides | 4 | 2018 | 497 | 1.060 |
Why?
| Glaucoma, Angle-Closure | 5 | 2018 | 16 | 1.030 |
Why?
| Corneal Diseases | 2 | 2024 | 34 | 1.020 |
Why?
| Lenses, Intraocular | 4 | 2020 | 43 | 1.010 |
Why?
| Lens, Crystalline | 2 | 2020 | 123 | 1.000 |
Why?
| Capsulorhexis | 2 | 2016 | 8 | 0.980 |
Why?
| Eye | 6 | 2013 | 105 | 0.940 |
Why?
| Polymers | 5 | 2011 | 479 | 0.940 |
Why?
| Macular Degeneration | 4 | 2010 | 159 | 0.940 |
Why?
| Microscopy | 4 | 2018 | 140 | 0.910 |
Why?
| Photons | 4 | 2016 | 67 | 0.910 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 107 | 0.870 |
Why?
| Optic Nerve Diseases | 2 | 2022 | 34 | 0.850 |
Why?
| Ophthalmologic Surgical Procedures | 4 | 2014 | 57 | 0.840 |
Why?
| Dry Eye Syndromes | 1 | 2024 | 54 | 0.840 |
Why?
| Endoscopy | 7 | 2018 | 290 | 0.840 |
Why?
| Pilocarpine | 2 | 2025 | 15 | 0.830 |
Why?
| Cell Survival | 8 | 2013 | 1086 | 0.800 |
Why?
| Aged | 43 | 2025 | 22107 | 0.800 |
Why?
| Brimonidine Tartrate | 3 | 2018 | 9 | 0.780 |
Why?
| Bevacizumab | 12 | 2021 | 128 | 0.760 |
Why?
| Antibodies, Monoclonal, Humanized | 12 | 2011 | 756 | 0.750 |
Why?
| Drug Packaging | 4 | 2015 | 41 | 0.750 |
Why?
| Visual Acuity | 11 | 2022 | 326 | 0.740 |
Why?
| Recombinant Fusion Proteins | 2 | 2015 | 650 | 0.730 |
Why?
| Laser Therapy | 3 | 2016 | 129 | 0.700 |
Why?
| Thiazines | 2 | 2018 | 9 | 0.690 |
Why?
| Prosthesis Design | 4 | 2016 | 309 | 0.680 |
Why?
| Epithelium, Corneal | 2 | 2010 | 40 | 0.680 |
Why?
| Spectrum Analysis, Raman | 4 | 2013 | 41 | 0.680 |
Why?
| Drug Combinations | 9 | 2017 | 331 | 0.660 |
Why?
| Thiophenes | 2 | 2011 | 117 | 0.660 |
Why?
| Sclera | 7 | 2015 | 36 | 0.660 |
Why?
| Vision Disorders | 3 | 2020 | 135 | 0.640 |
Why?
| Microscopy, Fluorescence, Multiphoton | 8 | 2016 | 66 | 0.640 |
Why?
| Aged, 80 and over | 21 | 2025 | 7066 | 0.630 |
Why?
| Middle Aged | 41 | 2025 | 31177 | 0.620 |
Why?
| beta-Alanine | 1 | 2019 | 16 | 0.620 |
Why?
| Benzoates | 1 | 2019 | 41 | 0.610 |
Why?
| Imaging, Three-Dimensional | 5 | 2016 | 530 | 0.610 |
Why?
| rho-Associated Kinases | 1 | 2019 | 87 | 0.580 |
Why?
| Ranibizumab | 8 | 2021 | 20 | 0.580 |
Why?
| Cells, Cultured | 12 | 2015 | 4102 | 0.580 |
Why?
| Male | 54 | 2025 | 63759 | 0.560 |
Why?
| Ocular Hypotension | 4 | 2022 | 10 | 0.560 |
Why?
| Treatment Outcome | 19 | 2025 | 10241 | 0.550 |
Why?
| Retinal Pigment Epithelium | 4 | 2015 | 70 | 0.550 |
Why?
| Prostaglandins F | 3 | 2011 | 17 | 0.550 |
Why?
| Equipment Design | 6 | 2018 | 514 | 0.540 |
Why?
| Anterior Capsule of the Lens | 1 | 2016 | 2 | 0.530 |
Why?
| Ophthalmology | 4 | 2022 | 82 | 0.530 |
Why?
| Prospective Studies | 14 | 2021 | 7158 | 0.520 |
Why?
| Patient Compliance | 4 | 2018 | 568 | 0.520 |
Why?
| Epithelial Cells | 3 | 2011 | 1063 | 0.510 |
Why?
| Retrospective Studies | 26 | 2025 | 14553 | 0.510 |
Why?
| Female | 51 | 2025 | 68829 | 0.500 |
Why?
| Intravitreal Injections | 6 | 2021 | 56 | 0.490 |
Why?
| Circadian Rhythm | 3 | 2023 | 416 | 0.490 |
Why?
| Oxidative Stress | 2 | 2013 | 1264 | 0.480 |
Why?
| Diabetic Retinopathy | 2 | 2023 | 179 | 0.480 |
Why?
| Wound Healing | 3 | 2012 | 308 | 0.480 |
Why?
| Uveitis | 3 | 2022 | 127 | 0.480 |
Why?
| Mitomycin | 3 | 2016 | 32 | 0.470 |
Why?
| Motivational Interviewing | 1 | 2016 | 101 | 0.470 |
Why?
| Reminder Systems | 1 | 2016 | 173 | 0.460 |
Why?
| Pharmaceutical Preparations | 2 | 2019 | 171 | 0.450 |
Why?
| Visual Fields | 3 | 2024 | 87 | 0.450 |
Why?
| Behavior Therapy | 1 | 2016 | 241 | 0.440 |
Why?
| Iris | 4 | 2013 | 19 | 0.440 |
Why?
| Patient Preference | 1 | 2016 | 184 | 0.430 |
Why?
| Injections | 6 | 2010 | 174 | 0.430 |
Why?
| Pyruvates | 1 | 2013 | 24 | 0.420 |
Why?
| Administration, Topical | 5 | 2016 | 147 | 0.420 |
Why?
| Cell Count | 4 | 2021 | 318 | 0.420 |
Why?
| Stainless Steel | 2 | 2010 | 21 | 0.420 |
Why?
| Pseudophakia | 2 | 2018 | 11 | 0.410 |
Why?
| Porphyrins | 1 | 2013 | 21 | 0.410 |
Why?
| Follow-Up Studies | 11 | 2025 | 4896 | 0.410 |
Why?
| Anterior Chamber | 2 | 2012 | 22 | 0.410 |
Why?
| Perception | 3 | 2021 | 347 | 0.410 |
Why?
| Triamcinolone Acetonide | 2 | 2014 | 27 | 0.410 |
Why?
| Photosensitizing Agents | 1 | 2013 | 32 | 0.400 |
Why?
| Goblet Cells | 2 | 2012 | 22 | 0.400 |
Why?
| Health Behavior | 2 | 2015 | 743 | 0.390 |
Why?
| Dose-Response Relationship, Drug | 6 | 2011 | 2016 | 0.390 |
Why?
| Telemedicine | 1 | 2021 | 792 | 0.380 |
Why?
| Rabbits | 7 | 2015 | 778 | 0.380 |
Why?
| Drugs, Generic | 1 | 2011 | 21 | 0.370 |
Why?
| Vitreous Body | 5 | 2010 | 109 | 0.360 |
Why?
| Drug Therapy | 1 | 2011 | 80 | 0.360 |
Why?
| Surgically-Created Structures | 1 | 2011 | 2 | 0.360 |
Why?
| NADP | 1 | 2011 | 47 | 0.360 |
Why?
| Adipocytes | 1 | 2012 | 205 | 0.350 |
Why?
| Fibrin Tissue Adhesive | 2 | 2010 | 13 | 0.350 |
Why?
| Tissue Adhesives | 2 | 2010 | 17 | 0.340 |
Why?
| Blood Pressure | 2 | 2017 | 1736 | 0.340 |
Why?
| Choroid | 1 | 2010 | 62 | 0.340 |
Why?
| Wet Macular Degeneration | 1 | 2010 | 45 | 0.330 |
Why?
| Endothelins | 1 | 2010 | 62 | 0.330 |
Why?
| Prescription Drugs | 1 | 2011 | 112 | 0.330 |
Why?
| Dexamethasone | 1 | 2012 | 352 | 0.320 |
Why?
| Hydrogen Peroxide | 1 | 2011 | 317 | 0.320 |
Why?
| Quinoxalines | 1 | 2009 | 64 | 0.310 |
Why?
| Adult | 20 | 2025 | 35634 | 0.310 |
Why?
| Particulate Matter | 2 | 2011 | 247 | 0.310 |
Why?
| Depressive Disorder | 1 | 2012 | 367 | 0.300 |
Why?
| Anxiety Disorders | 1 | 2012 | 357 | 0.300 |
Why?
| Anti-Infective Agents | 1 | 2011 | 249 | 0.300 |
Why?
| In Vitro Techniques | 4 | 2011 | 1092 | 0.300 |
Why?
| Diagnostic Techniques, Ophthalmological | 3 | 2020 | 38 | 0.300 |
Why?
| Collagen | 5 | 2016 | 438 | 0.300 |
Why?
| Surgical Wound Dehiscence | 1 | 2008 | 23 | 0.290 |
Why?
| Primary Health Care | 2 | 2009 | 1687 | 0.290 |
Why?
| Cognition Disorders | 1 | 2012 | 505 | 0.280 |
Why?
| Aqueous Humor | 4 | 2016 | 33 | 0.280 |
Why?
| Software | 1 | 2012 | 608 | 0.280 |
Why?
| Postoperative Period | 5 | 2025 | 330 | 0.280 |
Why?
| Neovascularization, Pathologic | 4 | 2013 | 297 | 0.270 |
Why?
| Retinoschisis | 1 | 2006 | 2 | 0.270 |
Why?
| Postoperative Complications | 7 | 2021 | 2481 | 0.270 |
Why?
| Animals | 22 | 2016 | 35409 | 0.260 |
Why?
| Endothelium, Corneal | 2 | 2021 | 16 | 0.260 |
Why?
| Fluorescence | 3 | 2011 | 156 | 0.260 |
Why?
| Trypan Blue | 1 | 2006 | 6 | 0.260 |
Why?
| Self Administration | 1 | 2007 | 122 | 0.260 |
Why?
| Reproducibility of Results | 7 | 2021 | 3089 | 0.260 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 1284 | 0.260 |
Why?
| Coloring Agents | 1 | 2006 | 78 | 0.250 |
Why?
| Carbohydrate Metabolism, Inborn Errors | 1 | 2006 | 2 | 0.250 |
Why?
| Optic Nerve | 1 | 2006 | 64 | 0.250 |
Why?
| Visual Field Tests | 2 | 2024 | 16 | 0.250 |
Why?
| Administration, Ophthalmic | 2 | 2019 | 15 | 0.250 |
Why?
| Eye Injuries | 2 | 2006 | 46 | 0.250 |
Why?
| Contact Lenses | 3 | 2020 | 9 | 0.250 |
Why?
| Iridectomy | 1 | 2005 | 1 | 0.250 |
Why?
| Pseudotumor Cerebri | 1 | 2006 | 25 | 0.240 |
Why?
| Retinal Degeneration | 1 | 2006 | 37 | 0.240 |
Why?
| Monitoring, Physiologic | 2 | 2018 | 266 | 0.240 |
Why?
| Acrylic Resins | 2 | 2016 | 44 | 0.240 |
Why?
| Histological Techniques | 2 | 2018 | 40 | 0.240 |
Why?
| Glucocorticoids | 2 | 2016 | 582 | 0.240 |
Why?
| Pilot Projects | 5 | 2018 | 1597 | 0.230 |
Why?
| Cadaver | 3 | 2016 | 308 | 0.230 |
Why?
| Alkylating Agents | 3 | 2016 | 24 | 0.220 |
Why?
| Retina | 3 | 2016 | 283 | 0.220 |
Why?
| United States Food and Drug Administration | 2 | 2015 | 205 | 0.210 |
Why?
| Image Processing, Computer-Assisted | 3 | 2013 | 739 | 0.210 |
Why?
| Case-Control Studies | 5 | 2024 | 3384 | 0.210 |
Why?
| Surveys and Questionnaires | 6 | 2022 | 5437 | 0.210 |
Why?
| Drug Stability | 3 | 2011 | 161 | 0.200 |
Why?
| Prostaglandins, Synthetic | 2 | 2013 | 5 | 0.200 |
Why?
| ROC Curve | 1 | 2024 | 504 | 0.200 |
Why?
| Titanium | 2 | 2014 | 76 | 0.200 |
Why?
| Wounds, Nonpenetrating | 1 | 2005 | 273 | 0.190 |
Why?
| Cross-Sectional Studies | 7 | 2022 | 5085 | 0.190 |
Why?
| Self Report | 2 | 2016 | 800 | 0.180 |
Why?
| Heart Rate | 2 | 2017 | 804 | 0.180 |
Why?
| Drug Storage | 2 | 2011 | 58 | 0.180 |
Why?
| Eye Diseases | 2 | 2013 | 82 | 0.170 |
Why?
| Young Adult | 8 | 2019 | 12467 | 0.170 |
Why?
| Legislation, Drug | 1 | 2020 | 77 | 0.160 |
Why?
| Specialization | 1 | 2020 | 145 | 0.160 |
Why?
| Postoperative Care | 3 | 2025 | 244 | 0.150 |
Why?
| Remote Sensing Technology | 1 | 2019 | 16 | 0.150 |
Why?
| Attitude | 1 | 2021 | 254 | 0.150 |
Why?
| Artificial Intelligence | 1 | 2022 | 245 | 0.150 |
Why?
| Biosensing Techniques | 1 | 2020 | 118 | 0.150 |
Why?
| Magnetic Resonance Imaging | 1 | 2010 | 3397 | 0.150 |
Why?
| Limbus Corneae | 2 | 2015 | 9 | 0.150 |
Why?
| Medical Marijuana | 1 | 2020 | 111 | 0.150 |
Why?
| Uveitis, Anterior | 1 | 2018 | 13 | 0.150 |
Why?
| Fibroblasts | 2 | 2013 | 954 | 0.140 |
Why?
| Medication Errors | 2 | 2015 | 96 | 0.140 |
Why?
| Double-Blind Method | 2 | 2019 | 1877 | 0.140 |
Why?
| Tropicamide | 1 | 2016 | 2 | 0.130 |
Why?
| Mydriatics | 1 | 2016 | 3 | 0.130 |
Why?
| Marijuana Use | 1 | 2020 | 192 | 0.130 |
Why?
| Marijuana Smoking | 1 | 2020 | 247 | 0.130 |
Why?
| Adrenergic beta-Antagonists | 1 | 2019 | 321 | 0.130 |
Why?
| Phenylephrine | 1 | 2016 | 75 | 0.130 |
Why?
| Burnout, Professional | 1 | 2022 | 411 | 0.120 |
Why?
| Endophthalmitis | 1 | 2016 | 28 | 0.120 |
Why?
| Delayed-Action Preparations | 2 | 2018 | 174 | 0.120 |
Why?
| Disease Management | 1 | 2019 | 592 | 0.120 |
Why?
| Fibrosis | 1 | 2018 | 526 | 0.120 |
Why?
| Coronary Artery Disease | 1 | 2022 | 680 | 0.120 |
Why?
| Artificial Lens Implant Migration | 1 | 2015 | 3 | 0.120 |
Why?
| Endothelial Cells | 1 | 2021 | 749 | 0.120 |
Why?
| Swine | 3 | 2013 | 761 | 0.120 |
Why?
| Hyaluronic Acid | 2 | 2008 | 216 | 0.120 |
Why?
| Alloys | 1 | 2015 | 34 | 0.120 |
Why?
| Diabetes Mellitus | 1 | 2023 | 1003 | 0.120 |
Why?
| Combined Modality Therapy | 2 | 2010 | 1201 | 0.120 |
Why?
| Capsule Opacification | 1 | 2015 | 22 | 0.120 |
Why?
| Surgical Flaps | 1 | 2016 | 136 | 0.120 |
Why?
| Lasers, Semiconductor | 1 | 2015 | 12 | 0.120 |
Why?
| Biodegradable Plastics | 1 | 2014 | 3 | 0.120 |
Why?
| Endpoint Determination | 1 | 2015 | 76 | 0.110 |
Why?
| Micelles | 1 | 2014 | 37 | 0.110 |
Why?
| Patient Acceptance of Health Care | 2 | 2018 | 763 | 0.110 |
Why?
| Viscosupplements | 1 | 2014 | 11 | 0.110 |
Why?
| Drug Therapy, Combination | 2 | 2018 | 1042 | 0.110 |
Why?
| Societies, Medical | 2 | 2015 | 759 | 0.110 |
Why?
| Cell Proliferation | 2 | 2012 | 2378 | 0.110 |
Why?
| Nickel | 1 | 2014 | 54 | 0.110 |
Why?
| Autopsy | 2 | 2011 | 92 | 0.110 |
Why?
| Referral and Consultation | 1 | 2019 | 735 | 0.110 |
Why?
| Disease Progression | 3 | 2024 | 2628 | 0.110 |
Why?
| Physicians | 1 | 2022 | 875 | 0.110 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 340 | 0.100 |
Why?
| Drug Synergism | 1 | 2014 | 370 | 0.100 |
Why?
| Gonioscopy | 1 | 2013 | 6 | 0.100 |
Why?
| Neuroprotective Agents | 1 | 2014 | 121 | 0.100 |
Why?
| Models, Psychological | 1 | 2015 | 308 | 0.100 |
Why?
| Protective Agents | 1 | 2013 | 39 | 0.100 |
Why?
| Macular Edema | 2 | 2016 | 43 | 0.100 |
Why?
| Tissue Scaffolds | 1 | 2015 | 203 | 0.100 |
Why?
| Photochemotherapy | 1 | 2013 | 32 | 0.100 |
Why?
| Antimetabolites | 1 | 2012 | 23 | 0.100 |
Why?
| Drug Monitoring | 1 | 2014 | 216 | 0.100 |
Why?
| Quality of Life | 1 | 2024 | 2695 | 0.100 |
Why?
| Manifest Anxiety Scale | 1 | 2012 | 4 | 0.100 |
Why?
| Pandemics | 1 | 2021 | 1500 | 0.100 |
Why?
| Patient Satisfaction | 1 | 2016 | 639 | 0.100 |
Why?
| Cross-Over Studies | 1 | 2014 | 521 | 0.090 |
Why?
| Melanins | 1 | 2011 | 18 | 0.090 |
Why?
| Drug Contamination | 1 | 2011 | 51 | 0.090 |
Why?
| Diagnostic Imaging | 1 | 2014 | 326 | 0.090 |
Why?
| Elastin | 1 | 2011 | 77 | 0.090 |
Why?
| Needles | 1 | 2012 | 57 | 0.090 |
Why?
| Fluoresceins | 1 | 2011 | 47 | 0.090 |
Why?
| Fluorescein-5-isothiocyanate | 1 | 2011 | 37 | 0.090 |
Why?
| Cattle | 1 | 2014 | 978 | 0.090 |
Why?
| Biocompatible Materials | 1 | 2015 | 404 | 0.090 |
Why?
| Cell Death | 1 | 2013 | 353 | 0.090 |
Why?
| Self Efficacy | 1 | 2015 | 377 | 0.090 |
Why?
| Memory Disorders | 1 | 2012 | 162 | 0.090 |
Why?
| Silicone Oils | 1 | 2011 | 26 | 0.090 |
Why?
| Fovea Centralis | 1 | 2010 | 11 | 0.090 |
Why?
| Psychometrics | 1 | 2015 | 701 | 0.090 |
Why?
| Lasers | 1 | 2011 | 133 | 0.090 |
Why?
| Dextrans | 1 | 2011 | 84 | 0.090 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2011 | 124 | 0.090 |
Why?
| Immunoglobulin Fragments | 1 | 2010 | 11 | 0.090 |
Why?
| Anti-Inflammatory Agents | 1 | 2014 | 482 | 0.090 |
Why?
| Retreatment | 1 | 2010 | 70 | 0.090 |
Why?
| Physician-Patient Relations | 1 | 2015 | 542 | 0.090 |
Why?
| Electromagnetic Fields | 1 | 2010 | 23 | 0.090 |
Why?
| Equipment Safety | 1 | 2010 | 37 | 0.090 |
Why?
| Microscopy, Electron, Scanning | 4 | 2015 | 196 | 0.080 |
Why?
| Geriatric Assessment | 1 | 2012 | 205 | 0.080 |
Why?
| Mice, Inbred C57BL | 4 | 2016 | 5468 | 0.080 |
Why?
| Chromatography, Gel | 1 | 2010 | 126 | 0.080 |
Why?
| Immunoglobulin Light Chains | 1 | 2010 | 40 | 0.080 |
Why?
| Motivation | 1 | 2015 | 548 | 0.080 |
Why?
| Immunoglobulin Heavy Chains | 1 | 2010 | 79 | 0.080 |
Why?
| Torque | 1 | 2010 | 83 | 0.080 |
Why?
| Molecular Weight | 1 | 2010 | 330 | 0.080 |
Why?
| Tissue Donors | 1 | 2012 | 391 | 0.080 |
Why?
| Protein Multimerization | 1 | 2011 | 179 | 0.080 |
Why?
| Aptamers, Nucleotide | 1 | 2010 | 77 | 0.080 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 338 | 0.080 |
Why?
| Microfluidic Analytical Techniques | 1 | 2010 | 73 | 0.080 |
Why?
| Endocrine System Diseases | 1 | 2009 | 33 | 0.080 |
Why?
| Fluorescent Dyes | 1 | 2011 | 313 | 0.080 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2011 | 585 | 0.080 |
Why?
| Communication | 1 | 2015 | 847 | 0.080 |
Why?
| Cell Separation | 1 | 2010 | 316 | 0.080 |
Why?
| Risk Assessment | 2 | 2020 | 3269 | 0.080 |
Why?
| Suture Techniques | 1 | 2010 | 118 | 0.080 |
Why?
| Microscopy, Confocal | 1 | 2010 | 318 | 0.080 |
Why?
| Reference Values | 1 | 2010 | 796 | 0.080 |
Why?
| Sodium Chloride | 1 | 2009 | 138 | 0.080 |
Why?
| Vasoconstriction | 1 | 2010 | 199 | 0.080 |
Why?
| Ocular Motility Disorders | 1 | 2009 | 26 | 0.080 |
Why?
| Amphetamine-Related Disorders | 1 | 2009 | 36 | 0.080 |
Why?
| Risk Factors | 3 | 2018 | 9801 | 0.080 |
Why?
| Microscopy, Fluorescence | 1 | 2010 | 399 | 0.070 |
Why?
| Choroidal Neovascularization | 1 | 2009 | 55 | 0.070 |
Why?
| Tandem Mass Spectrometry | 1 | 2011 | 528 | 0.070 |
Why?
| Retinal Vein Occlusion | 1 | 2008 | 13 | 0.070 |
Why?
| Chondroitin | 1 | 2008 | 5 | 0.070 |
Why?
| Methamphetamine | 1 | 2009 | 55 | 0.070 |
Why?
| Fluorescein | 1 | 2008 | 25 | 0.070 |
Why?
| Microvilli | 1 | 2008 | 79 | 0.070 |
Why?
| Kaplan-Meier Estimate | 1 | 2010 | 851 | 0.070 |
Why?
| Rupture | 1 | 2008 | 92 | 0.070 |
Why?
| Lymphocyte Count | 1 | 2008 | 148 | 0.070 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 836 | 0.070 |
Why?
| Time Factors | 3 | 2019 | 6550 | 0.070 |
Why?
| Immunosuppressive Agents | 1 | 2012 | 858 | 0.070 |
Why?
| Vitamins | 1 | 2009 | 173 | 0.070 |
Why?
| Mice | 6 | 2016 | 16983 | 0.070 |
Why?
| Neuropsychological Tests | 1 | 2012 | 1016 | 0.070 |
Why?
| Central Nervous System Stimulants | 1 | 2009 | 154 | 0.070 |
Why?
| United States | 5 | 2022 | 13913 | 0.070 |
Why?
| Cell Line | 1 | 2013 | 2780 | 0.070 |
Why?
| Perioperative Care | 2 | 2019 | 166 | 0.070 |
Why?
| Inflammation | 1 | 2018 | 2748 | 0.070 |
Why?
| Mice, Inbred BALB C | 3 | 2015 | 1248 | 0.070 |
Why?
| Molteno Implants | 1 | 2006 | 2 | 0.060 |
Why?
| Uveal Diseases | 1 | 2006 | 5 | 0.060 |
Why?
| Conjunctivitis | 1 | 2006 | 30 | 0.060 |
Why?
| Sutures | 1 | 2006 | 53 | 0.060 |
Why?
| Glucosyltransferases | 1 | 2006 | 3 | 0.060 |
Why?
| Sweat Gland Neoplasms | 1 | 2006 | 6 | 0.060 |
Why?
| Scleral Buckling | 1 | 2006 | 18 | 0.060 |
Why?
| Eyelid Neoplasms | 1 | 2006 | 9 | 0.060 |
Why?
| Lymphocytes | 1 | 2008 | 377 | 0.060 |
Why?
| Motorcycles | 1 | 2005 | 6 | 0.060 |
Why?
| Glycosylation | 1 | 2006 | 153 | 0.060 |
Why?
| Sensitivity and Specificity | 2 | 2024 | 1847 | 0.060 |
Why?
| Prevalence | 1 | 2012 | 2564 | 0.060 |
Why?
| Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| Muscarinic Agonists | 1 | 2025 | 16 | 0.060 |
Why?
| Sleep | 2 | 2023 | 689 | 0.060 |
Why?
| Forecasting | 1 | 2007 | 361 | 0.060 |
Why?
| Adenocarcinoma, Mucinous | 1 | 2006 | 73 | 0.060 |
Why?
| Syndrome | 1 | 2006 | 338 | 0.060 |
Why?
| Treatment Failure | 1 | 2006 | 339 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2023 | 1951 | 0.060 |
Why?
| Accidents, Traffic | 1 | 2005 | 184 | 0.050 |
Why?
| Vietnam | 1 | 2023 | 26 | 0.050 |
Why?
| Optical Imaging | 2 | 2015 | 56 | 0.050 |
Why?
| Incidence | 1 | 2010 | 2646 | 0.050 |
Why?
| Materials Testing | 2 | 2015 | 349 | 0.050 |
Why?
| Area Under Curve | 1 | 2024 | 306 | 0.050 |
Why?
| Reoperation | 1 | 2006 | 542 | 0.050 |
Why?
| Photography | 1 | 2023 | 93 | 0.050 |
Why?
| Injections, Intraocular | 2 | 2014 | 10 | 0.050 |
Why?
| Sex Factors | 1 | 2009 | 1973 | 0.050 |
Why?
| Apoptosis | 1 | 2011 | 2489 | 0.050 |
Why?
| Clinical Trials as Topic | 1 | 2007 | 1005 | 0.050 |
Why?
| Age Factors | 1 | 2009 | 3161 | 0.050 |
Why?
| Manometry | 1 | 2021 | 92 | 0.040 |
Why?
| Prognosis | 2 | 2020 | 3773 | 0.040 |
Why?
| Coronary Angiography | 1 | 2022 | 306 | 0.040 |
Why?
| Membrane Proteins | 1 | 2006 | 1119 | 0.040 |
Why?
| Carbonic Anhydrase Inhibitors | 1 | 2018 | 14 | 0.040 |
Why?
| Preoperative Period | 1 | 2019 | 116 | 0.040 |
Why?
| Adolescent | 4 | 2019 | 20451 | 0.040 |
Why?
| Axial Length, Eye | 1 | 2018 | 15 | 0.040 |
Why?
| Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| Corneal Pachymetry | 1 | 2018 | 15 | 0.040 |
Why?
| Drug Resistance | 1 | 2018 | 165 | 0.040 |
Why?
| Refraction, Ocular | 1 | 2018 | 36 | 0.040 |
Why?
| Pupil | 1 | 2016 | 13 | 0.030 |
Why?
| Rats | 2 | 2016 | 5487 | 0.030 |
Why?
| Neurites | 1 | 2016 | 47 | 0.030 |
Why?
| Biomimetics | 1 | 2016 | 43 | 0.030 |
Why?
| Nerve Regeneration | 1 | 2016 | 62 | 0.030 |
Why?
| Fluoroquinolones | 1 | 2016 | 45 | 0.030 |
Why?
| Prednisolone | 1 | 2016 | 82 | 0.030 |
Why?
| Color Perception Tests | 1 | 2015 | 3 | 0.030 |
Why?
| Slit Lamp | 1 | 2015 | 2 | 0.030 |
Why?
| Macaca fascicularis | 1 | 2015 | 63 | 0.030 |
Why?
| Medical Device Legislation | 1 | 2015 | 2 | 0.030 |
Why?
| Opossums | 1 | 2015 | 9 | 0.030 |
Why?
| Anterior Eye Segment | 1 | 2015 | 9 | 0.030 |
Why?
| Device Approval | 1 | 2015 | 21 | 0.030 |
Why?
| Color | 1 | 2015 | 73 | 0.030 |
Why?
| Muscle, Smooth | 1 | 2016 | 160 | 0.030 |
Why?
| False Positive Reactions | 1 | 2015 | 114 | 0.030 |
Why?
| Academies and Institutes | 1 | 2015 | 50 | 0.030 |
Why?
| Device Removal | 1 | 2016 | 136 | 0.030 |
Why?
| Mutation | 1 | 2006 | 3706 | 0.030 |
Why?
| Axons | 1 | 2016 | 193 | 0.030 |
Why?
| Validation Studies as Topic | 1 | 2014 | 21 | 0.030 |
Why?
| Membrane Lipids | 1 | 2015 | 91 | 0.030 |
Why?
| Drug Utilization | 1 | 2015 | 171 | 0.030 |
Why?
| Diffusion of Innovation | 1 | 2015 | 97 | 0.030 |
Why?
| Models, Animal | 1 | 2016 | 376 | 0.030 |
Why?
| Quality Control | 1 | 2014 | 162 | 0.030 |
Why?
| Reference Standards | 1 | 2014 | 176 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2014 | 171 | 0.030 |
Why?
| Corneal Stroma | 1 | 2013 | 17 | 0.030 |
Why?
| Photoreceptor Cells, Vertebrate | 1 | 2013 | 26 | 0.030 |
Why?
| Staining and Labeling | 1 | 2013 | 143 | 0.030 |
Why?
| Histocytochemistry | 1 | 2013 | 80 | 0.030 |
Why?
| Finite Element Analysis | 1 | 2012 | 72 | 0.020 |
Why?
| Lipid Metabolism | 1 | 2015 | 503 | 0.020 |
Why?
| Biological Availability | 1 | 2012 | 147 | 0.020 |
Why?
| Permeability | 1 | 2012 | 158 | 0.020 |
Why?
| Attitude to Health | 1 | 2015 | 433 | 0.020 |
Why?
| Spectrometry, Fluorescence | 1 | 2012 | 164 | 0.020 |
Why?
| Models, Statistical | 1 | 2015 | 624 | 0.020 |
Why?
| Chronic Disease | 2 | 2008 | 1724 | 0.020 |
Why?
| Massage | 1 | 2011 | 43 | 0.020 |
Why?
| Drug Compounding | 1 | 2011 | 97 | 0.020 |
Why?
| Diagnostic Techniques, Endocrine | 1 | 2009 | 14 | 0.020 |
Why?
| Stress, Mechanical | 1 | 2012 | 467 | 0.020 |
Why?
| Particle Size | 1 | 2011 | 355 | 0.020 |
Why?
| Cohort Studies | 1 | 2019 | 5444 | 0.020 |
Why?
| Ultrasonography | 1 | 2011 | 713 | 0.020 |
Why?
| Pigment Epithelium of Eye | 1 | 2006 | 35 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 2016 | 1708 | 0.020 |
Why?
| Mohs Surgery | 1 | 2006 | 25 | 0.020 |
Why?
| Radiotherapy, Adjuvant | 1 | 2006 | 208 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2006 | 766 | 0.010 |
Why?
| Biomarkers | 1 | 2015 | 3971 | 0.010 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2009 | 573 | 0.010 |
Why?
| Biopsy | 1 | 2006 | 1089 | 0.010 |
Why?
| Diagnosis, Differential | 1 | 2006 | 1434 | 0.010 |
Why?
| Pregnancy | 1 | 2009 | 6423 | 0.010 |
Why?
| Infant | 1 | 2010 | 9018 | 0.010 |
Why?
| Child, Preschool | 1 | 2010 | 10522 | 0.010 |
Why?
| Child | 1 | 2010 | 20962 | 0.010 |
Why?
|
|
Kahook's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|